Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-HER2-DM1 ADC B003

An antibody-drug conjugate (ADC) consisting of a recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC), with potential antineoplastic activity. Upon administration of B003, the anti-HER2 monoclonal antibody moiety targets and binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics, inhibiting cell division and the proliferation of cancer cells that overexpress HER2.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC B003
anti-HER2-DM1 antibody-drug conjugate B003
recombinant humanized anti-HER2 monoclonal antibody-MCC-DM1 B003
Code name:B 003
B-003
B003
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search